OncoOne is a biotech start-up dedicated to developing innovative therapeutics to treat patients with solid tumors, founded by three individuals with a long history in drug development and oncology research from the pharmaceutical industry.
The aim of OncoOne is to be a research engine for anti-cancer medicines that meet serious unmet medical needs in oncology. Our passion for science is at the core of everything we do to build a differentiated pipeline of potent therapeutics. Our entrepreneurial spirit enables us to link innovation with corporate strategies.
We are a team of experienced professionals.
Randolf Kerschbaumer, PhD
Founder & Chief Executive Officer
Randolf has more than 20 years of experience in academic and big pharma R&D and acquired detailed knowledge of the entire drug development process, from early drug screening to clinical development. He is in charge of executive management, fundraising, patenting and business development.
Michael Thiele, PhD
Founder & Chief Scientific Officer
Michael is a renowned expert in immunology, tumor biology, biomarkers and the development of biologics. He leads the OncoOne biology team. Michael is responsible for managing preclinical studies and for conducting research on drug/target mechanisms in biological systems.
Alexander Schinagl, PhD
Founder & Chief Technology Officer
Alexander has a broad knowledge of molecular biology, biochemistry and cell biology techniques in the field of oncology and inflammation. He is in charge of the OncoOne protein sciences team. Alexander oversees the implementation of the technologies used for the production and analysis of the company’s therapeutics.